Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The objective of this single-arm feasibility study is to investigate the safety and impact of the topical EPC Silver Wound Gel (EPC-123) in the management of diabetic foot ulcer wounds not progressing under the current standard of care.
The objective of the proposed work is 1) to monitor clinical safety of EPC Silver Wound Gel on diabetic foot ulcers, 2) to evaluate the clinical impact of EPC Silver Wound Gel in foot ulcer progression in conjunction with the standard of care 3) to quantify the changes within the wound bacterial environment as it impacts wound healing and 4) to evaluate subjective patient and clinician outcomes: satisfaction, quality of life, perceived benefit, and compliance.
Consenting subjects who qualify for enrollment will proceed with two, weekly, visits related to screening. If screen passed, ie. under the current standard of care no progression of the diabetic foot ulcer is observed in accordance with validated diabetic foot ulcer classification metrics, then the subject will proceed with two weeks of study period where twice weekly clinic and twice weekly intermediate home-based care. This may be followed by an additional two weeks of study period, if warranted in accordance with best practice, with once weekly clinic and intermediate home care visits. In total there will be up to 9 clinic visits (minimum 7 clinic visits up to 9 clinic visits) in 6 weeks (screening and trial visits; minimum 4 weeks up to a maximum of 6 weeks).
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Experimental | A prospective, single-arm, repeated measures feasibility study will be coordinated on the use of EPC Silver Wound Gel in patients with diabetic foot ulcers and localized infections within an outpatient clinical setting, to determine the safety of EPC Silver Wound Gel on diabetic foot ulcerations and impact on wound infection classification, wound ecology, and immunological biomarkers, in conjunction with the standard of care, to clarify parameters for a potential future study. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| EPC Silver Wound Gel | Device | Re-application of EPC-123 will occur within 48 hours of the initial application. Secondary dressings will be selected at the discretion of the clinician or home care provider, based upon best practice guidelines for moisture management and will consist of a selection between the following secondary dressings: Mesorb® (Molnyke), Gauze, Cling (self-adherent gauze), or MediporeTM (3M). Application of EPC-123 will be executed at the Lawson Health Research Institute every second visit, where interim applications will be facilitated by home care. To support home care applications, a study kit will be provided to home care professionals inclusive of the EPC Silver Wound Gel, secondary dressings required, and instructions for removal/re-application. |
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of intervention-related adverse events collected throughout the trial | Clinical and/or biological adverse events will be reported over the intervention period. Severity of any adverse events will be graded. | Up to 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| Qualitative improvement in quality of life assessment during the intervention period compared with screening period under standard of care. | Quality of life will be assessed using the qualitative "Wound QoL" tool during the intervention period compared with qualitative assessment at baseline. | Up to 28 days |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Lawson Health Research Institute | London | Ontario | N6C0A7 | Canada |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32209136 | Background | Armstrong DG, Swerdlow MA, Armstrong AA, Conte MS, Padula WV, Bus SA. Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer. J Foot Ankle Res. 2020 Mar 24;13(1):16. doi: 10.1186/s13047-020-00383-2. | |
| 32105420 | Background | Boulton AJM, Armstrong DG, Hardman MJ, Malone M, Embil JM, Attinger CE, Lipsky BA, Aragon-Sanchez J, Li HK, Schultz G, Kirsner RS. Diagnosis and Management of Diabetic Foot Infections. Arlington (VA): American Diabetes Association; 2020 Jan. Available from http://www.ncbi.nlm.nih.gov/books/NBK554227/ |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D017719 | Diabetic Foot |
| ID | Term |
|---|---|
| D003925 | Diabetic Angiopathies |
| D014652 | Vascular Diseases |
| D002318 | Cardiovascular Diseases |
| D016523 | Foot Ulcer |
Not provided
Not provided
A prospective, single-arm, repeated measures study feasibility study will be coordinated by the Lawson Health Research Institute on the use of EPC Silver Wound Gel (EPC-123) in patients with diabetic foot ulcers and localized infections within an outpatient clinical setting, to determine the safety of EPC Silver Wound Gel on diabetic foot ulcerations and impact on wound infection, wound ecology, and immunological biomarkers, in conjunction with the standard of care, to clarify parameters for a potential future study.
Not provided
Not provided
Patients will be assigned an internal ID number
Not provided
|
| Progression of the Infectious Diseases Society of America and International Working Group on the Diabetic Foot Classifications of Diabetic Foot Infection during the intervention period compared with screening period under standard of care. |
Progressions of PEDIS (grade 1 = no symptoms or signs of infection; to grade 4, local infection with the signs of systemic inflammatory response syndrome) or IDSA Infection Severity (Uninfected; to Severe) during the intervention period compared with screening period under standard of care. |
| Up to 42 days |
| Progression the Diabetic Foot Infection (DFI) Wound Score during the intervention period compared with screening period under standard of care. | Signs and symptoms of infection will be assessed using the 10-item DFI Wound Score system inclusive of semi-quantitative measurement of purulent discharge, non-purulent discharge, erythema, induration, tenderness, pain, warmth, size, depth, undermining. The DFI Wound Score ranges from a score of 3 (less severe wound) to 49 (more severe wound). Rate of change in DFI score during the intervention period will be compared with screening period under standard of care. | Up to 42 days |
| Progression the Bioburden Assessment Tool (BAT) during the intervention period compared with screening period under standard of care. | The degree of bioburden will be assessed using BAT; measuring for the presence or absence of signs and symptoms of infection and bioburden and subsequent clinical interpretation. Progressions of the level of bioburden risk, from Category I (colonized: at risk) to Category VI (systemic infection), during the intervention period will be compared with screening period under standard of care. | Up to 42 days |
| Early clinical response | Quantitation of lesion erythema area and wound area at 48-72 hours following the first intervention application. | Within 48-72 hours of first intervention application |
| Number of participants with systemic antibiotic or antifungal drug administration over the course of the intervention versus screening and baseline. | Report on the number of participants receiving administration of systemic antibiotic or antifungal drugs during the intervention period compared with screening period under standard of care. | Up to 42 days |
| Progression in the absolute number of critical or qualified pathogen species present within the wound microbiome over the course of the intervention versus screening and baseline. | Progression in the absolute number of critical or qualified pathogens (inclusive of those pathogens identified by the Centre for Disease Control and Prevention, World Health Organization, and the FDA as per 79 FR 32464) as per gene pyrosequencing over the course of intervention versus screening and baseline. | Up to 42 days |
| Progression in the relative quantity of critical or qualified pathogens versus commensal organisms present within the wound microbiome over the course of the intervention versus screening and baseline. | Progression in the relative composition of critical or qualified pathogens (inclusive of those pathogens identified by the Centre for Disease Control and Prevention, World Health Organization, and the FDA as per 79 FR 32464) versus commensal organisms in the wound microbiome of as per gene pyrosequencing over the course of intervention versus screening and baseline. | Up to 42 days |
| Progression in wound microbiome over the course of the intervention versus screening and baseline. | Progression of the wound microbiome on a whole ecology basis as per gene pyrosequencing; evaluating for community membership, structure, and diversity over the course of intervention versus screening and baseline. | Up to 42 days |
| Percent change in wound area and volume during the intervention period compared to baseline. | Percent change in wound volume (cm3) at each visit compared to baseline. | Up to 28 days |
| Rate of wound closure, specifically percent change in area, during the intervention period compared with screening period under standard of care. | Rate of wound closure, change in wound area (cm2), over the course of the intervention period compared to the screening period. | Up to 42 days |
| Rate of wound closure, specifically percent change in volume, during the intervention period compared with screening period under standard of care. | Rate of wound closure, change in wound volume (cm3), over the course of the intervention period compared to the screening period. | Up to 42 days |
| Qualitative evaluation of patient satisfaction via questionnaire. | Patient satisfaction over the course of the intervention period will evaluated. Patient satisfaction of the performance of the intervention will be evaluated within a rating scale of "poor" through to "excellent". | Up to 28 days |
| Qualitative evaluation of clinician satisfaction via questionnaire. | Clinician satisfaction over the course of the intervention period will evaluated. Clinician satisfaction of the performance of the intervention will be evaluated within a rating scale of "poor" through to "excellent". | Up to 28 days |
| Progression of systemic biomarker C-Reactive protein (CRP). | Quantitation of clinical change in CRP (mg/L) from baseline to end of intervention period. | Up to 28 days |
| Progression of systemic biomarker Erythrocyte sedimentation rate (ESR). | Quantitation of clinical change in ESR (mm/hr) from baseline to end of intervention period. | Up to 28 days |
| Progression of systemic biomarker CBC and Differential. | Quantitation of clinical change in CBC and Differential (cells per cubic millimeter) from baseline to end of intervention period. | Up to 28 days |
| Progression of systemic biomarker body temperature. | Quantitation of clinical change in body temperature (degree Celsius) over the course of the intervention versus screening and baseline. | Up to 42 days |
| Progression in peri-wound microbiome over the course of the intervention versus screening and baseline. | Progression of the peri-wound microbiome on a whole ecology basis as per gene pyrosequencing; evaluating for community membership, structure, and diversity over the course of intervention versus screening and baseline. | Up to 42 days |
| Quantitative progression of local inflammatory biomarkers over the course of the intervention versus screening and baseline. | Quantitation of host inflammatory cytokines and chemokines (pg/ml) inclusive of: IL-1, IL-6, IL-8, IL-10 TNF-α, MMP-8, MMP-9, MMP-2, TIMP1, and TIMP2; within the wound over the course of the intervention versus screening and baseline. | Up to 42 days |
| 22619242 | Background | Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, Deery HG, Embil JM, Joseph WS, Karchmer AW, Pinzur MS, Senneville E; Infectious Diseases Society of America. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012 Jun;54(12):e132-73. doi: 10.1093/cid/cis346. |
| 19671126 | Background | Lipsky BA, Polis AB, Lantz KC, Norquist JM, Abramson MA. The value of a wound score for diabetic foot infections in predicting treatment outcome: a prospective analysis from the SIDESTEP trial. Wound Repair Regen. 2009 Sep-Oct;17(5):671-7. doi: 10.1111/j.1524-475X.2009.00521.x. Epub 2009 Aug 11. |
| 32176444 | Background | Lipsky BA, Senneville E, Abbas ZG, Aragon-Sanchez J, Diggle M, Embil JM, Kono S, Lavery LA, Malone M, van Asten SA, Urbancic-Rovan V, Peters EJG; International Working Group on the Diabetic Foot (IWGDF). Guidelines on the diagnosis and treatment of foot infection in persons with diabetes (IWGDF 2019 update). Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3280. doi: 10.1002/dmrr.3280. |
| 24899053 | Background | Blome C, Baade K, Debus ES, Price P, Augustin M. The "Wound-QoL": a short questionnaire measuring quality of life in patients with chronic wounds based on three established disease-specific instruments. Wound Repair Regen. 2014 Jul-Aug;22(4):504-14. doi: 10.1111/wrr.12193. |
| 10788924 | Background | Houghton PE, Kincaid CB, Campbell KE, Woodbury MG, Keast DH. Photographic assessment of the appearance of chronic pressure and leg ulcers. Ostomy Wound Manage. 2000 Apr;46(4):20-6, 28-30. |
| D007871 |
| Leg Ulcer |
| D012883 | Skin Ulcer |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D048909 | Diabetes Complications |
| D003920 | Diabetes Mellitus |
| D004700 | Endocrine System Diseases |
| D003929 | Diabetic Neuropathies |